DUBLIN--(BUSINESS WIRE)-- <\/p>\n
Research and Markets (http:\/\/www.researchandmarkets.com\/research\/v55pln\/moderate<\/a>) has announced the addition of the \"Moderate Psoriasis - Pipeline Review, H2 2013\" report to their offering. <\/p>\n 'Moderate Psoriasis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Moderate Psoriasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Moderate Psoriasis. <\/p>\n Scope <\/p>\n - A snapshot of the global therapeutic scenario for Moderate Psoriasis. <\/p>\n - A review of the Moderate Psoriasis products under development by companies and universities\/research institutes based on information derived from company and industry-specific sources. <\/p>\n - Coverage of products based on various stages of development ranging from discovery till registration stages. <\/p>\n - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. <\/p>\n - Coverage of the Moderate Psoriasis pipeline on the basis of route of administration and molecule type. <\/p>\n - Key discontinued pipeline projects. <\/p>\n <\/p>\n More: DUBLIN--(BUSINESS WIRE)-- Research and Markets (http:\/\/www.researchandmarkets.com\/research\/v55pln\/moderate<\/a>) has announced the addition of the \"Moderate Psoriasis - Pipeline Review, H2 2013\" report to their offering. 'Moderate Psoriasis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. Continue reading
\nResearch and Markets: Moderate Psoriasis - Pipeline Review, H2 2013<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"